Device developers who want to use a Predetermined Change Control Plan (PCCP) during the US Food and Drug Administration’s premarket review process shouldn’t skimp on the detail, FDA officials say.
“A good rule of thumb is that generally, the level of detail expected in a PCCP should be the same as would be submitted in a marketing submission for a particular modification, but minus the test data,” explained device center
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?